It won’t be licensing deals as the platform has to many...

It won’t be licensing deals as the platform has to many indications...potentially 60+...It’ll be a bid, probably after they see results on the open label PD1 which will be after HerVaxx has proved up it’s Phase2 trial or maybe before if they’re seeing compelling results in the open label PD1 trial.
For 60plus indications that show no toxicity and increases life expectancy it’ll be an eye watering amount.

Maybe 2 Bids...1 for the BCell platform and another for CF33...
For CF33 if either leg of the trial comes in and works as well they think it could be Billions for this alone, but if the intravenous leg comes in, it’ll be a ground breaker and who knows what that’ll be worth but it will be serious money.
Interesting on the numbers for HerVaxx that they had the soft lock applied in the Sept qtr, therefore when they announced the reduction on the numbers last week they still would’ve been recruiting for at least 2 months. It may not be 5 more but much less...looking forward to hearing that the trial has been fully recruited, could be sooner than we think.